<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7249458\results\search\disease\results.xml">
  <result pre="Original Articles Role of Tissue Engineering in COVID-19 and Future" exact="Viral" post="Outbreaks TataraAlexander M.MD, PhD[], Address correspondence to: Alexander M."/>
  <result pre="PhD[], Address correspondence to: Alexander M. Tatara, MD, PhD, Massachusetts" exact="General" post="Hospital, Department of Medicine, 55 Fruit Street, Boston, MA"/>
  <result pre="the current novel coronavirus (COVID-19) pandemic, as well as other" exact="viral" post="outbreaks in the 21st century, there is a dire"/>
  <result pre="dire need for new diagnostic and therapeutic strategies to combat" exact="infectious diseases" post="worldwide. As a convergence science, tissue engineering has traditionally"/>
  <result pre="to apply their skill set to the current crisis and" exact="viral" post="outbreaks in general. This work introduces the basics of"/>
  <result pre="is clear need for advances in diagnostics and therapeutics for" exact="viral" post="outbreaks. Tissue engineering has the potential for critical impact"/>
  <result pre="has the potential for critical impact on clinical outcomes in" exact="viral" post="outbreaks. Tissue engineers, if mobilized, could play key roles"/>
  <result pre="could be applied to the current COVID-19 crisis and future" exact="viral" post="outbreaks are highlighted. tissue engineering biomaterials pandemic coronavirus viral"/>
  <result pre="future viral outbreaks are highlighted. tissue engineering biomaterials pandemic coronavirus" exact="viral" post="fig-count: ref-count: page-count: Introduction As of April 2020 ,"/>
  <result pre="1,500,000 patients worldwide have been diagnosed with the novel coronavirus" exact="disease" post="2019 (COVID-2019) caused by a laboratory-confirmed infection of the"/>
  <result pre="the novel coronavirus disease 2019 (COVID-2019) caused by a laboratory-confirmed" exact="infection" post="of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),"/>
  <result pre="disease 2019 (COVID-2019) caused by a laboratory-confirmed infection of the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with more than"/>
  <result pre="2019 (COVID-2019) caused by a laboratory-confirmed infection of the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with more than 84,000"/>
  <result pre="(COVID-2019) caused by a laboratory-confirmed infection of the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2), with more than 84,000 global"/>
  <result pre="caused by a laboratory-confirmed infection of the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2), with more than 84,000 global deaths"/>
  <result pre="Our hospital systems are rapidly filling with patients suffering from" exact="viral" post="illness, and the capacity of resources such as emergency"/>
  <result pre="after the predicted resolution of COVID-19, the increasing frequency of" exact="viral" post="outbreaks (including the 2003 Severe Acute Respiratory Syndrome Coronavirus,2"/>
  <result pre="COVID-19, the increasing frequency of viral outbreaks (including the 2003" exact="Severe" post="Acute Respiratory Syndrome Coronavirus,2 2014 Ebola virus,3 2015 Middle"/>
  <result pre="the increasing frequency of viral outbreaks (including the 2003 Severe" exact="Acute" post="Respiratory Syndrome Coronavirus,2 2014 Ebola virus,3 2015 Middle Eastern"/>
  <result pre="increasing frequency of viral outbreaks (including the 2003 Severe Acute" exact="Respiratory" post="Syndrome Coronavirus,2 2014 Ebola virus,3 2015 Middle Eastern Respiratory"/>
  <result pre="frequency of viral outbreaks (including the 2003 Severe Acute Respiratory" exact="Syndrome" post="Coronavirus,2 2014 Ebola virus,3 2015 Middle Eastern Respiratory Syndrome"/>
  <result pre="Acute Respiratory Syndrome Coronavirus,2 2014 Ebola virus,3 2015 Middle Eastern" exact="Respiratory" post="Syndrome Coronavirus,4 and 2015 Zika virus outbreaks5) suggests that"/>
  <result pre="Respiratory Syndrome Coronavirus,2 2014 Ebola virus,3 2015 Middle Eastern Respiratory" exact="Syndrome" post="Coronavirus,4 and 2015 Zika virus outbreaks5) suggests that new"/>
  <result pre="2015 Zika virus outbreaks5) suggests that new mechanisms to combat" exact="viral" post="infections are a high priority. As a convergence science,"/>
  <result pre="Zika virus outbreaks5) suggests that new mechanisms to combat viral" exact="infections" post="are a high priority. As a convergence science, tissue"/>
  <result pre="revolutionize areas in medicine such as high-throughput drug discovery,6 personalized" exact="cancer" post="therapy,7 immune modulation,8 and organ transplantation.9 Tissue engineers specialize"/>
  <result pre="States alone as of 2017.12 In the current setting of" exact="limited" post="clinical data and rising patient morbidity and mortality, tissue"/>
  <result pre="in improving clinical outcomes during the COVID-19 pandemic and future" exact="viral" post="epidemics is explored (Fig. 1). Relevant background information regarding"/>
  <result pre="and pertinent tissue engineering work is highlighted, including development of" exact="viral" post="in vitro models, drug delivery systems, and vaccine platforms."/>
  <result pre="level. In addition, many major academic centers are currently at" exact="limited" post="capacity due to precautions to limit the spread of"/>
  <result pre="to lead the way to prevent and treat the next" exact="viral" post="epidemic better. FIG. 1. Examples of how tissue engineering"/>
  <result pre="an impact on clinical practice in the setting of a" exact="viral" post="outbreak. Our current understanding of SARS-CoV-2 is evolving and"/>
  <result pre="blocking ACE2 interactions, altering endosome pH to prevent escape, inhibiting" exact="viral" post="and/or host enzymes critical to replication, and downregulating host"/>
  <result pre="host inflammation, given that an overexuberant response may lead to" exact="acute" post="respiratory distress syndrome (ARDS).16 SARS-CoV-2 has the highest viral"/>
  <result pre="inflammation, given that an overexuberant response may lead to acute" exact="respiratory" post="distress syndrome (ARDS).16 SARS-CoV-2 has the highest viral burden"/>
  <result pre="that an overexuberant response may lead to acute respiratory distress" exact="syndrome" post="(ARDS).16 SARS-CoV-2 has the highest viral burden in the"/>
  <result pre="to acute respiratory distress syndrome (ARDS).16 SARS-CoV-2 has the highest" exact="viral" post="burden in the nares rather than the throat and"/>
  <result pre="fatigue and, less commonly, gastrointestinal manifestations.19 Current biomarkers suggestive of" exact="infection" post="include elevated lactate dehydrogenase, ferritin, D-dimer, erythrocyte sedimentation rate,"/>
  <result pre="contributions for COVID-19, the next coronavirus epidemic, or other future" exact="viral" post="outbreaks. In Vitro Models Development of physiologically representative in"/>
  <result pre="Vitro Models Development of physiologically representative in vitro models of" exact="viral" post="disease can assist in two critical roles during a"/>
  <result pre="Models Development of physiologically representative in vitro models of viral" exact="disease" post="can assist in two critical roles during a pandemic:"/>
  <result pre="in vitro modeling to understand host response as well as" exact="viral" post="mechanisms for transmission and replication is critical for the"/>
  <result pre="culture of Vero cells, an interferon-deficient aneuploid line of kidney" exact="epithelial" post="cells originally isolated from an African green monkey.25,26 In"/>
  <result pre="aneuploid line of kidney epithelial cells originally isolated from an" exact="African" post="green monkey.25,26 In a recent study, Vero cells were"/>
  <result pre="In general, the relevance of a drug's ability to inhibit" exact="viral infection" post="of a malignant nonhuman primate (NHP) kidney cell lacking"/>
  <result pre="general, the relevance of a drug's ability to inhibit viral" exact="infection" post="of a malignant nonhuman primate (NHP) kidney cell lacking"/>
  <result pre="of a drug's ability to inhibit viral infection of a" exact="malignant" post="nonhuman primate (NHP) kidney cell lacking interferon production is"/>
  <result pre="(ECM), three-dimensional cellâ€&quot;cell interfaces, and shear forces. Coronaviruses and other" exact="respiratory" post="viruses, for example, can bind to the ECM components"/>
  <result pre="the ECM components such as sialic acid to assist in" exact="infection" post="of the host.30 In the last decade, tissue engineering"/>
  <result pre="been able to mimic complex pathophysiology such as generation of" exact="pulmonary" post="edema upon exposure to inflammatory signals such as interleukin-2.31"/>
  <result pre="A virus, 3D tissue-engineered constructs more accurately recapitulated the host" exact="morphology" post="of cultured human epithelial airway cells compared to 2D"/>
  <result pre="constructs more accurately recapitulated the host morphology of cultured human" exact="epithelial" post="airway cells compared to 2D culture, and infection with"/>
  <result pre="cultured human epithelial airway cells compared to 2D culture, and" exact="infection" post="with major influenza strains resulted in upregulation of proinflammatory"/>
  <result pre="cytokines.32 One coronavirus-specific example of a tissue-engineered platform in which" exact="respiratory" post="viruses have been studied is the rotation wall vessel"/>
  <result pre="models simulate low physiologic shear stresses and frequently incorporate multiple" exact="pulmonary" post="cell types, including co-culture of human mesenchymal bronchial tracheal"/>
  <result pre="co-culture of human mesenchymal bronchial tracheal cells and human bronchial" exact="epithelial" post="cells, challenging them against respiratory syncytial virus and SARS-CoV-1.33"/>
  <result pre="tracheal cells and human bronchial epithelial cells, challenging them against" exact="respiratory" post="syncytial virus and SARS-CoV-1.33 Unfortunately, SARS-CoV-1 did not replicate"/>
  <result pre="did not replicate in this study.34 In another model, human" exact="pulmonary" post="epithelial progenitor cells were grown on a collagen matrix"/>
  <result pre="not replicate in this study.34 In another model, human pulmonary" exact="epithelial" post="progenitor cells were grown on a collagen matrix in"/>
  <result pre="by SARS-CoV-1, which may suggest why normal lung regeneration following" exact="viral infection" post="is challenging.35 There are a number of exciting tissue-engineered"/>
  <result pre="SARS-CoV-1, which may suggest why normal lung regeneration following viral" exact="infection" post="is challenging.35 There are a number of exciting tissue-engineered"/>
  <result pre="lung models currently available that could be leveraged for studying" exact="viral" post="infection36,37 and established in vivo models for respiratory viruses,"/>
  <result pre="for studying viral infection36,37 and established in vivo models for" exact="respiratory" post="viruses, including NHPs, already in use.38â€&quot;40 Elements that may"/>
  <result pre="human rather than animal cell lines; (2) co-culture of multiple" exact="pulmonary" post="cell lines; (3) 3D scaffolds that mimic native pulmonary"/>
  <result pre="multiple pulmonary cell lines; (3) 3D scaffolds that mimic native" exact="pulmonary" post="architecture; and (4) culture methods that permit generation of"/>
  <result pre="(4) culture methods that permit generation of ECM prior to" exact="viral" post="inoculation. Additional head-to-head studies will need to be performed"/>
  <result pre="if these components are necessary to capture the pathophysiology of" exact="viral infection." post="These platforms will be important in conducting hypothesis-driven research"/>
  <result pre="identify therapeutic candidates for in vivo translation rapidly during major" exact="infectious" post="outbreaks. Drug Delivery Systems During the COVID-19 pandemic, one"/>
  <result pre="discussed previously regarding in vitro drug screens, there are currently" exact="limited" post="therapeutics that have clear clinical evidence of improving outcomes"/>
  <result pre="combination of hydroxychloroquine (a small molecule traditionally used to treat" exact="malaria" post="and lupus) and azithromycin (a macrolide antibiotic with anti-inflammatory"/>
  <result pre="properties) has been suggested as a means to reduce SARS-CoV-2" exact="viral" post="load, although these results are controversial.44 Poly(lactide) and poly(lactide-co-glycolide)"/>
  <result pre="the lungs, resulting in higher local concentrations in a murine" exact="pneumonia" post="model compared to oral and intravenous routes of delivery.46"/>
  <result pre="be engineered to block specific ligands or receptors vital for" exact="viral" post="function. These therapies generally need to be delivered intravenously"/>
  <result pre="delivery of medications previously only efficacious in intravenous form.53 Lastly," exact="short" post="interfering RNA (siRNA) has also been explored as both"/>
  <result pre="siRNA was effective in a NHP model,39 resulting in diminished" exact="viral" post="load and alveolar damage. Four intranasal doses were required"/>
  <result pre="siRNA such as polyethylenimine due to the possibility of carrier-induced" exact="lung inflammation." post="However, more complex vehicles have since been developed by"/>
  <result pre="vehicles have since been developed by the field specifically for" exact="pulmonary" post="usage, including mesoporous silica nanoparticles55 and cationic liposomes.56 As"/>
  <result pre="their work in designing vehicles to target areas of high" exact="viral" post="load specifically and extendedly. Even if this work may"/>
  <result pre="current pandemic, these vehicles may serve vital roles during future" exact="viral" post="outbreaks. Vaccine Platforms The ability to vaccinate against specific"/>
  <result pre="preventative medicine for the last century. Vaccines exist both for" exact="respiratory" post="viruses such as Influenzavirus and for bacteria such as"/>
  <result pre="as Streptococcus pneumoniae and Haemophilus influenzae. While the success of" exact="respiratory" post="viral vaccines varies from season to season, data suggest"/>
  <result pre="Streptococcus pneumoniae and Haemophilus influenzae. While the success of respiratory" exact="viral" post="vaccines varies from season to season, data suggest influenza"/>
  <result pre="season to season, data suggest influenza vaccination generally results in" exact="lower" post="probability of complications, including ICU stay, mechanical ventilation, and"/>
  <result pre="and severe outcomes, especially in patients with comorbidities such as" exact="chronic" post="obstructive pulmonary disease.57â€&quot;59 Work is already underway to develop"/>
  <result pre="outcomes, especially in patients with comorbidities such as chronic obstructive" exact="pulmonary" post="disease.57â€&quot;59 Work is already underway to develop vaccines effective"/>
  <result pre="already underway to develop vaccines effective against SARS-CoV-2 to prevent" exact="disease" post="and mitigate transmission.60 Successful vaccination against pathogens relies on"/>
  <result pre="response in a murine model.65 Biodegradable polymers, one of the" exact="primary" post="workhorses as scaffold material in tissue engineering, have also"/>
  <result pre="to no carriers and other biomaterials in a vaccine against" exact="Chagas disease" post="in a murine model66 and have also been explored"/>
  <result pre="no carriers and other biomaterials in a vaccine against Chagas" exact="disease" post="in a murine model66 and have also been explored"/>
  <result pre="murine model, chitosan nanoparticles enhanced T-cell response for a Mycobacterium" exact="tuberculosis" post="DNA vaccine.69 When chitosan was mannosylated to promote endocytosis,"/>
  <result pre="SARS-CoV-1 peptide sequence, and subsequent sera was successful in preventing" exact="infection" post="of Vero cells.72 In addition to various particle-based platforms,"/>
  <result pre="to vaccine components. This strategy has primarily been applied to" exact="tumor" post="vaccines and has demonstrated efficacy in animal models against"/>
  <result pre="tumor vaccines and has demonstrated efficacy in animal models against" exact="melanoma" post="and intracranial gliomas.73,76 It is currently undergoing a Phase"/>
  <result pre="trial of 23 patients with melanoma, which is estimated to" exact="complete" post="in June 2020 (NCT01753089; ClinicalTrials.gov). This platform of scaffold-based"/>
  <result pre="This platform of scaffold-based vaccination has also shown efficacy against" exact="bacterial" post="pathogens in porcine and murine models.77 Other examples of"/>
  <result pre="Other examples of scaffold-based vaccine systems include those generated from" exact="respiratory" post="syncytial virus that were effective in mice as well"/>
  <result pre="a global health-care crisis of unheralded magnitude. The rate of" exact="infection" post="and mortality from COVID-19 make it unlike any virus"/>
  <result pre="tools and can make substantial contributions to our understanding of" exact="viral" post="disease and contribute toward the critical development of diagnostic"/>
  <result pre="and can make substantial contributions to our understanding of viral" exact="disease" post="and contribute toward the critical development of diagnostic and"/>
  <result pre="this current pandemic and work to prevent and mitigate future" exact="viral" post="outbreaks. Acknowledgments I would like to thank my co-residents"/>
  <result pre="I would like to thank my co-residents at the Massachusetts" exact="General" post="Hospital for their selfless service on the front lines"/>
  <result pre="for this work. References References 1.collab: World Health Organization. Coronavirus" exact="disease" post="(COVID-19) pandemic. World Health Organization, 2020 2.BellD.M.; World Health"/>
  <result pre="al.Assessing the international spreading risk associated with the 2014 West" exact="African" post="Ebola outbreak. PLoS Curr6,2014 4.ChoS.Y., KangJ.M., HaY.E., et al.MERS-CoV"/>
  <result pre="6.MazzocchiA., SokerS., and SkardalA.3D bioprinting for high-throughput screening: drug screening," exact="disease" post="modeling, and precision medicine applications. Appl Phys Rev6,011302, 2019"/>
  <result pre="WanX., YangJ., et al.A 3D in vitro model of patient-derived" exact="prostate cancer" post="xenograft for controlled interrogation of in vivo tumor-stromal interactions."/>
  <result pre="YangJ., et al.A 3D in vitro model of patient-derived prostate" exact="cancer" post="xenograft for controlled interrogation of in vivo tumor-stromal interactions."/>
  <result pre="p. 1 15.ZhengY.-Y., MaY.-T., ZhangJ.-Y., and XieX. COVID-19 and the" exact="cardiovascular" post="system. Nat Rev Cardiol 2020 [Epub ahead of print];"/>
  <result pre="HongZ.-S., et al.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;an update on the status. Mil Med"/>
  <result pre="status. Mil Med Res7,11, 202032169119 17.ZouL., RuanF., HuangM., et al.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patients. New"/>
  <result pre="Res7,11, 202032169119 17.ZouL., RuanF., HuangM., et al.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patients. New Engl J Med382,1177,"/>
  <result pre="202032169119 17.ZouL., RuanF., HuangM., et al.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patients. New Engl J Med382,1177, 202032074444"/>
  <result pre="DOI: 10.1515/cclm-2020-0198 21.ToK.K.-W., TsangO.T.-Y., LeungW.-S., et al. Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
  <result pre="TsangO.T.-Y., LeungW.-S., et al. Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect Dis"/>
  <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
  <result pre="print]; DOI: 10.1016/S0140-6736(20)30627-9 24.XieJ., HungerfordD., ChenH., et al. Development and" exact="external" post="validation of a prognostic multivariable model on admission for"/>
  <result pre="SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is enriched in specific cell subsets across"/>
  <result pre="coronaviruses. Glycoconj J23,51, 200616575522 31.HuhD., LeslieD.C., MatthewsB.D., et al.A human" exact="disease" post="model of drug toxicity-induced pulmonary edema in a lung-on-a-chip"/>
  <result pre="LeslieD.C., MatthewsB.D., et al.A human disease model of drug toxicity-induced" exact="pulmonary" post="edema in a lung-on-a-chip microdevice. Sci Transl Med4,159ra147, 2012"/>
  <result pre="interactions. Viruses8,2016 34.SudermanM., McCarthyM., MossellE., et al. Three-dimensional human bronchial-tracheal" exact="epithelial" post="tissue-like assemblies (TLAs) as hosts for severe acute respiratory"/>
  <result pre="human bronchial-tracheal epithelial tissue-like assemblies (TLAs) as hosts for severe" exact="acute" post="respiratory syndrome (SARS)-CoV infection. NASA/TP-2006-213723. NASA, 2006 35.LingT.Y., KuoM.D.,"/>
  <result pre="bronchial-tracheal epithelial tissue-like assemblies (TLAs) as hosts for severe acute" exact="respiratory" post="syndrome (SARS)-CoV infection. NASA/TP-2006-213723. NASA, 2006 35.LingT.Y., KuoM.D., LiC.L.,"/>
  <result pre="epithelial tissue-like assemblies (TLAs) as hosts for severe acute respiratory" exact="syndrome" post="(SARS)-CoV infection. NASA/TP-2006-213723. NASA, 2006 35.LingT.Y., KuoM.D., LiC.L., et"/>
  <result pre="infection. NASA/TP-2006-213723. NASA, 2006 35.LingT.Y., KuoM.D., LiC.L., et al.Identification of" exact="pulmonary" post="Oct-4+ stem/progenitor cells and demonstration of their susceptibility to"/>
  <result pre="al.Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their" exact="susceptibility to" post="SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad"/>
  <result pre="cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV)" exact="infection" post="in vitro. Proc Natl Acad Sci U S A103,9530,"/>
  <result pre="36.MillerA.J., and SpenceJ.R.In vitro models to study human lung development," exact="disease" post="and homeostasis. Physiology (Bethesda)32,246, 201728404740 37.NicholsJ.E., NilesJ.A., VegaS.P., and"/>
  <result pre="Physiology (Bethesda)32,246, 201728404740 37.NicholsJ.E., NilesJ.A., VegaS.P., and CortiellaJ.Novel in vitro" exact="respiratory" post="models to study lung development, physiology, pathology and toxicology."/>
  <result pre="BrinkE.N., et al.Human monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferrets. Lancet363,2139, 200415220038 39.LiB.-j., TangQ., ChengD., et al.Using"/>
  <result pre="GuenP., VilleretB., et al.Silver nanoparticle-adjuvanted vaccine protects against lethal influenza" exact="infection" post="through inducing BALT and IgA-mediated mucosal immunity. Biomaterials217,119308, 201931279103"/>
  <result pre="201222583850 46.WangQ., MiG., HickeyD., et al.Azithromycin-loaded respirable microparticles for targeted" exact="pulmonary" post="delivery for the treatment of pneumonia. Biomaterials160,107, 201829407340 47.TettS.,"/>
  <result pre="in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic" exact="lymphocytic leukemia" post="cells in vitro. Cancer Biother Radiopharm25,97, 201020187802 49.MulanguS., DoddL.E.,"/>
  <result pre="a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic" exact="leukemia" post="cells in vitro. Cancer Biother Radiopharm25,97, 201020187802 49.MulanguS., DoddL.E.,"/>
  <result pre="overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro." exact="Cancer" post="Biother Radiopharm25,97, 201020187802 49.MulanguS., DoddL.E., DaveyR.T.Jr., et al.A randomized,"/>
  <result pre="DoddL.E., DaveyR.T.Jr., et al.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. New Engl J Med381,2293, 201931774950 50.TianX., LiC., HuangA.,"/>
  <result pre="55.ChenY., GuH., ZhangD.S.-Z., LiF., LiuT., and XiaW.Highly effective inhibition of" exact="lung cancer" post="growth and metastasis by systemic delivery of siRNA via"/>
  <result pre="GuH., ZhangD.S.-Z., LiF., LiuT., and XiaW.Highly effective inhibition of lung" exact="cancer" post="growth and metastasis by systemic delivery of siRNA via"/>
  <result pre="LiuT., and XiaW.Highly effective inhibition of lung cancer growth and" exact="metastasis" post="by systemic delivery of siRNA via multimodal mesoporous silica-based"/>
  <result pre="XiaW.Highly effective inhibition of lung cancer growth and metastasis by" exact="systemic" post="delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials35,10058,"/>
  <result pre="59.PooleP.J., ChackoE., Wood-BakerR.W., and CatesC.J. Influenza vaccine for patients with" exact="chronic" post="obstructive pulmonary disease. Cochrane Database Syst Rev CD002733, 2006"/>
  <result pre="Wood-BakerR.W., and CatesC.J. Influenza vaccine for patients with chronic obstructive" exact="pulmonary" post="disease. Cochrane Database Syst Rev CD002733, 2006 60.ChenW.H., StrychU.,"/>
  <result pre="vaccine against Trypanosoma cruzi in a BALB/c mouse model of" exact="Chagas disease." post="Hum Vaccin Immunother12,976, 201626890466 67.PrimardC., RochereauN., LucianiE., et al.Traffic"/>
  <result pre="encoding T cell epitopes of Esat-6 and FL against Mycobacterium" exact="tuberculosis" post="infection. PLoS One8,e61135, 201323637790 70.YaoW., PengY., DuM., LuoJ., and"/>
  <result pre="intended for nasal mucosal delivery enhance immune responses and potent" exact="tumor" post="immunity. Mol Pharm10,2904, 201323768205 71.WuY., WeiW., ZhouM., et al.Thermal-sensitive"/>
  <result pre="as novel immunogens: design and analysis of a prototypic severe" exact="acute" post="respiratory syndrome vaccine. Chem Biol Drug Design73,53, 2009 73.AliO.A.,"/>
  <result pre="novel immunogens: design and analysis of a prototypic severe acute" exact="respiratory" post="syndrome vaccine. Chem Biol Drug Design73,53, 2009 73.AliO.A., DohertyE.,"/>
  <result pre="immunogens: design and analysis of a prototypic severe acute respiratory" exact="syndrome" post="vaccine. Chem Biol Drug Design73,53, 2009 73.AliO.A., DohertyE., MooneyD.J.,"/>
  <result pre="the kinetics of DC and T-cell responses induced by PLG-based" exact="cancer" post="vaccines. Biomatter1,66, 201123507728 74.AliO.A., EmerichD., DranoffG., and MooneyD.J.In situ"/>
  <result pre="MooneyD.J.In situ regulation of DC subsets and T cells mediates" exact="tumor" post="regression in mice. Sci Transl Med1,8ra19, 2009 75.KimJ., LiW.A.,"/>
  <result pre="DohertyE., BellW.J., et al.Biomaterial-based vaccine induces regression of established intracranial" exact="glioma" post="in rats. Pharm Res28,1074, 201121225320 77.SuperM., DohertyE.J., CartwrightM.J., et"/>
  <result pre="al. Modular biomaterials vaccine technology protects against multiple pathogens and" exact="septic shock." post="bioRxiv 2020 [Epub ahead of print]; DOI: 10.1101/2020.02.25/964601 78.CorreiaB.E.,"/>
  <result pre="vaccine design. Nature507,201, 201424499818 79.LuoX., LiuT., WangY., et al.An epitope-specific" exact="respiratory" post="syncytial virus vaccine based on an antibody scaffold. Angew"/>
 </snippets>
</snippetsTree>
